Acclarent Secures $26,000,000 Series D Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    1525-B O’Brien Drive Menlo Park, CA 94025
  • Company Description
    Initially, we are focused on achieving the goals of sinus surgery with novel, endoscopic, catheter-based tools – Balloon SinuplastyTM devices. Through the Balloon SinuplastyTM technology and our Relieva® product portfolio we offer ENT patients alternatives to conventional endoscopic surgical approaches. FDA clearances for these devices were completed in 2005 and the products were commercially launched in the US that same year.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series D
  • Proceeds Purposes
    Acclarent intends to use the proceeds to continue commercialization of its Balloon Sinuplasty(TM) Technology, as well as on-going investment in product development and clinical studies.
  • M&A Terms
  • Venture Investor
    Johnson & Johnson Development Corporation
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    Delphi Ventures
  • Venture Investor
    Versant Ventures
  • Venture Investor
    Meritech Capital Partners

Trending on Xconomy